NHD Global
Healing & Tissue Repair · Source-reviewed dossier
Source-Reviewed Research Dossier
TB-500 is a trade-style research name associated in the literature with an N-terminal acetylated thymosin-β4 fragment, while some catalogs use it for full-length thymosin β4. The exact sequence must therefore be confirmed from the specification rather than inferred from the name.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2012 paper synthesized and characterized the N-terminal-acetylated thymosin β4 17–23 fragment found in a suspected doping product.
The record shows why “TB-500” cannot automatically be treated as full-length thymosin β4.
Read the primary studyA 2026 rat study reported histopathological and biomechanical outcomes for TB-500, BPC-157 and their combination.
Preclinical results do not establish human efficacy or catalog-lot identity.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
The record shows why “TB-500” cannot automatically be treated as full-length thymosin β4.
View primary recordPreclinical results do not establish human efficacy or catalog-lot identity.
View primary recordThird-party publications selected for direct relevance.
Analytical study. 2012. PMID 22962027.
Biçer O, et al. Jt Dis Relat Surg. 2026;37:822–837. PMID 42542926.
Concise answers for researchers comparing identity, evidence and catalog variants.
TB-500 is a trade-style research name associated in the literature with an N-terminal acetylated thymosin-β4 fragment, while some catalogs use it for full-length thymosin β4. The exact sequence must therefore be confirmed from the specification rather than inferred from the name.
The public evidence is preclinical and includes a direct analytical description of the 17–23 fragment sold under the TB-500 name.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
A source-led analysis of the 2026 BPC-157 and TB-500 rat Achilles tendon study, including group design, histology, biomechanics and the absence of an added…
Updated August 28, 2026
A critical review of the limited human evidence for BPC-157 and TB-500, current FDA-identified safety information gaps and the quality questions a research catalog…
Updated August 28, 2026Source-traceable evidence
Structured readings of published studies, with the model, result and translation boundary stated explicitly.
A preclinical evidence case covering the four randomized rat groups, the split biomechanical and histology samples, statistically significant findings and the absence of an added combination…
Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: BT2 · 2 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
